- In March 2025, during DCAT Week, leading pharmaceutical manufacturers highlighted a major transition towards continuous biologics manufacturing. Companies such as Enzene Biosciences unveiled fully connected continuous bioprocessing platforms, which integrate upstream and downstream operations, enabling up to 10-fold increases in productivity and cost reductions—marking a transformative step for biopharmaceutical production
- In March 2022, USP India extended its presence in Hyderabad, announcing plans for a new continuous manufacturing facility with an added capital injection of USD 20 million. This expansion underscores USP's commitment to enhancing its operations and services in India's pharmaceutical sector
- In March 2022, Phlow Corp, a U.S. based public benefit company specializing in essential medicines, partnered with Virginia Commonwealth University (VCU) Medicines for All Institute and AMPAC Fine Chemicals. The collaboration aims to offer contract research and development services for small molecule pharmaceutical products, focusing on continuous manufacturing, thereby bolstering the pharmaceutical industry's capabilities and innovation
